Erbamont/Unigene calcitonin production
Executive SummaryTwo firms announced development of a procedure that enables production of larger quantities of the hormone. They explained that a strain of bacteria able to synthesize high levels of an inactive precursor of calcitonin was genetically engineered. "Specific conversion of the C-terminus of this substrate to the active amidated product was then accomplished" using Unigene's single-step amidation process, the companies reported. The naturally occurring peptide stimulates the incorporation of calcium into bones.
You may also be interested in...
The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.